HDL and cardiovascular disease

Stephen J. Nicholls; Adam J. Nelson

doi:10.1016/j.pathol.2018.10.017

HDL and cardiovascular disease

Stephen J. Nicholls, Adam J. Nelson

Heart And Vascular Health

Research output: Contribution to journal › Review article › peer-review

56 Citations (Scopus)

Abstract

High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

Original language	English
Pages (from-to)	142-147
Number of pages	6
Journal	Pathology
Volume	51
Issue number	2
DOIs	https://doi.org/10.1016/j.pathol.2018.10.017
Publication status	Published or Issued - Feb 2019

Keywords

HDL
atherosclerosis
cardiovascular risk
clinical trials
lipids

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1016/j.pathol.2018.10.017

Cite this

@article{a7224f15836c446c9b26936516d7e916,

title = "HDL and cardiovascular disease",

abstract = "High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.",

keywords = "HDL, atherosclerosis, cardiovascular risk, clinical trials, lipids",

author = "Nicholls, {Stephen J.} and Nelson, {Adam J.}",

note = "Publisher Copyright: {\textcopyright} 2018 Royal College of Pathologists of Australasia",

year = "2019",

month = feb,

doi = "10.1016/j.pathol.2018.10.017",

language = "English",

volume = "51",

pages = "142--147",

journal = "Pathology",

issn = "0031-3025",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - HDL and cardiovascular disease

AU - Nicholls, Stephen J.

AU - Nelson, Adam J.

PY - 2019/2

Y1 - 2019/2

N2 - High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

AB - High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

KW - HDL

KW - atherosclerosis

KW - cardiovascular risk

KW - clinical trials

KW - lipids

UR - http://www.scopus.com/inward/record.url?scp=85059137508&partnerID=8YFLogxK

U2 - 10.1016/j.pathol.2018.10.017

DO - 10.1016/j.pathol.2018.10.017

M3 - Review article

C2 - 30612759

AN - SCOPUS:85059137508

SN - 0031-3025

VL - 51

SP - 142

EP - 147

JO - Pathology

JF - Pathology

IS - 2

ER -

HDL and cardiovascular disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this